PLA2R1 and nephrotic syndrome: Hamilton et al. [34,35] conducted a prospective single-arm multicenter study, enrolling 12 patients with nephrotic syndrome due to primary membranous nephropathy and anti-PLA2R antibody levels >170 U/mL resistant after 6 months of symptomatic treatment.